Basic Information:
Product | 4-Chlorodehydromethyltestosterone |
CAS | 2446-23-3 |
Assay | 99% min. |
Molecular Fomular | C20H27ClO2 |
Molecular Weight | 334.8802 |
Molecular structure | |
Packing | foil bag or tin. |
Delivery | Express courier |
Character | White crystalline powder |
Description:
Turinabol is a safe steroid and often described as having properties somewhere between Dianabol, and Anavar. Turinabol is not able to aromatase into estrogen, so estrogenic side-effects are rare, however some reports have been given of mild gynocomastia symptoms. The exact cause is not entirely certain, but there is the possibility of Turinabol having some action on the estrogen receptor. Another possibility is for methyltestosterone contamination during the manufacturing process. Androgenic side-effects are still possible, but they are unlikely to be severe.
Turinabol is a c17 alpha alkylated steroid, so the possibility of liver damage should be taken into account when designing a cycle that includes it. Its good practice to keep dosages within reasonable levels and the duration of usage should be limited to around 6 weeks to avoid hepatotoxicity. Also use liver detoxification supplements.
Daily dosages are in the ranges of 40 to 60mg and Turinabol makes a great addition to cutting or pre-contest stacks. Versatility is a very positive aspect of this steroid and even athletes in sports where speed is required will find Turinabol a suitable performance enhancing drug. The strong anabolic effects without the added weight gain from water-retention are very favorable.
Dosing:
Men:
A common clinical dose of Oral Turinabol is estimated to be 5 mg per day; actual prescribing guidelines are unavailable. In the athletic arena, an effective oral daily dosage falls in the range of 15-40 mg, taken in cycles lasting no more than 6-8 weeks to minimize hepatotoxicity. This level is sufficient for measurable increases in lean muscle mass and strength.
This agent is most often applied as a pre-contest or cutting steroid for bodybuilding purposes, and is not viewed as an ideal bulking agent due to its lack of estrogenicity. Athletes in sports where speed tends to be a primary focus also find strong favor in chlorodehydromethyltestosterone, obtaining a strong anabolic benefit without having to carry around any extra water or fat weight.
Women:
A common clinical dose of Oral Turinabol is estimated to be 1-2.5 mg per day; actual prescribing guidelines are unavailable. In the athletic arena, women would commonly take a single 5 mg tablet per day, taken in cycles lasting no more than 4-6 weeks to minimize hepatotoxicity. Virilizing effects are unlikely at this level of use. Much higher doses were often used with female athletes in the former GDR doping program, but often to detriment of strong virilizing side effects.
COA:
Product Name | 4-Chlorotestosterone acetate | |||
Product Spec | 97.0~103.0% | Production Bath | 20170312 | |
CAS | 855-19-6 | Production Date | 2017-03-12 | |
Specification | Enterprise Standard | Shelf life | 2019-03-11 | |
Quantity | 7KG | Analysis Date | 2017-03-12 | |
Result For Analysis | ||||
Items of analysis | Specification | Results | ||
Identification | TLC: Should be the same as the principal spot reference solution |
Conforms | ||
IR: should be consistent with the reference spectra |
||||
Appearance | White crystalline powder | white powder | ||
Melting point | 220~230ºC | 222.5ºC | ||
Optical rotation | +112°~+120° | +116° | ||
Residue on ignition | ≤0.05% | 0.02% | ||
Solubility | practically insoluble in water, freely soluble in chloroform, slight soluble alcohol |
Conforms | ||
Heavy metal | ≤20ppm | 10ppm | ||
Related impurities | Single impurity ≤1.0% | 0.31% | ||
Any other impurity ≤0.5% | 0.2% | |||
Total impurity ≤1.5% | 0.5% | |||
Organic solvent residual amount |
Acetone ≤5000ppm | 300ppm | ||
Methanol ≤3000ppm | 130ppm | |||
Pyridine ≤200ppm | Conforms | |||
Methylene chloride ≤600ppm | 70ppm | |||
Loss on drying | ≤0.5% | 0.22% | ||
Assay | 97.0~103.0% | 99.02% | ||
Conclusion | Conforms Enterprise Standard. |